Abstract
The results of a study on the immunobiological properties of a new, naturally attenuated, unencapsulated Bacillus anthracis 363/11 strain in comparison with the properties of the anthrax vaccine strain 55-VNIIVVIM, which is currently used in Russia and post-Soviet states, are presented in the article. Some differences in the phenotypes of the aforementioned strains are shown. The new strain caused lysis of sheep erythrocytes by α- but not by β-type; the strain had many more active proteinases and synthesized protocatechuic acid (PCA), in contrast to the vaccine strain. It was ascertained that immunization of animals by the new strain protects them from death after infection by field isolates of B. anthracis, while the 55-VNIIVVIM strain does not create this immunity. The data indicate that the new strain can be used to develop and improve anthrax prevention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
